Analysts list AUD 4.37 target for 4Dmedical stock

Published on 10/27/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

4DMedical's AGM is scheduled for October 28, 2026. 4DMedical stock costs EUR 2.27 on October 27, 2026 at 6:42 p.m. CEST after hours.

Analyst target and AGM date

Simply Wall St lists an AUD 4.37 consensus target for 4DMedical on October 27, 2026.
4DMedical's annual general meeting is scheduled for October 28, 2026.
4DMedical stock costs EUR 2.27 at Lang & Schwarz on October 27, 2026 at 6:42 p.m. CEST.
The company has a market capitalization of AUD 2.2 billion and an AUD 1.40 to AUD 7.55 52-week range.

4Dmedical, AU0000095416, Illustration mit AI erstellt.

4DMedical stock has an AUD 4.37 consensus target listed by Simply Wall St, putting the target 21.05 percent above the AUD 3.61 ASX price on October 27, 2026. The annual general meeting is scheduled for October 28, 2026, while the euro quotation stood at EUR 2.27 at Lang & Schwarz on October 27, 2026 at 6:42 p.m. CEST.

AUD 4.37 target sets the benchmark

Simply Wall St lists three analysts and an AUD 4.37 consensus target for 4DMedical. Against the AUD 3.61 ASX price, that implies 21.05 percent upside to the target, calculated from the two AUD values. The comparison is a valuation reference rather than a forecast by this article.

ASX range leaves room to move

4DMedical's ASX quote was AUD 3.61 on October 27, 2026 at 4:10 p.m. AEDT. The same market snapshot places the 52-week range at AUD 1.40 to AUD 7.55, while the market capitalization stands at AUD 2.2 billion. The current quote is 52.19 percent below the 52-week high and 157.86 percent above the 52-week low.

Annual meeting brings the next date

According to the company's 4DMedical addendum dated October 16, 2026, the annual general meeting will take place on October 28, 2026. The document adds a resolution on the re-election of Professor Christine Jenkins, who joined the board on September 23, 2026.

What does the business provide?

4DMedical describes itself as a medical technology company developing advanced diagnostic imaging solutions for respiratory care. Its investor materials identify XV Technology and Imbio Technology as the main platforms, with non-invasive imaging designed to support physician assessment of lung function.

Trading stays tied to execution

The target comparison and the wide AUD 1.40 to AUD 7.55 range point to a stock whose valuation depends on commercial adoption. The October 28 meeting gives investors a dated corporate checkpoint, while the AUD 2.2 billion capitalization shows that the market already assigns substantial value to the technology platform.

Euro quote after the Xetra session

At Lang & Schwarz, 4DMedical stood at EUR 2.27 on October 27, 2026 at 6:42 p.m. CEST in after-hours trading. The further course of trading is shown by the continuously updated real-time quote of 4Dmedical stock.